InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,789.36
(
-2.59%
)
Post# of 252503
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: jq1234 post# 118083

Monday, 04/11/2011 9:15:13 PM

Monday, April 11, 2011 9:15:13 PM

Post# of 252503

why don't they think others in their pipleline could have similar fate?



The traditional criticism of EXEL was that they put a lot of low-quality drugs into the clinic and so had a huge spend. I think they were smart to become a pure play on XL184 (plus stuff they have already partnered out). If they win big on 184 they can always resuscitate their other programs.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up